TITLE:
Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

CONDITION:
Chronic Heart Failure

INTERVENTION:
conivaptan

SUMMARY:

      This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine
      the effects of conivaptan in patients with acute decompensated heart failure.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients may be male or female age 18 years or older.

          -  Women must be post-menopausal or surgically sterile.

          -  Patients must have chronic heart failure of at least 2 months duration and be
             hospitalized for the treatment of worsening heart failure. The primary manifestation
             of worsening heart failure must be worsening dyspnea.
      
